Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective direct-acting antiviral or 'DAA' medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    DAAs target different steps of HCV reproduction. These include HCV protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens include at least two drugs that work in different...

    From: Booklets

    Information level Level 2
  • Treatment for people with HIV and HCV co-infection

    In the UK, standards for HIV treatment and care are set and monitored by the British HIV Association (BHIVA), the professional association for HIV doctors and other healthcare...

    From: Booklets

    Information level Level 2
  • Hepatitis C and HIV

    Hepatitis C is a blood-borne infection that is transmitted in some of the same ways as HIV.Over time untreated hepatitis C...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • France: people who inject drugs often given cheaper, less effective, hepatitis C medication

    People living with HIV and hepatitis C (HCV) who have a history of injecting drug use are being offered less effective, but cheaper, HCV medication than other people with HIV/HCV co-infections, new research from France finds.

    17 July 2018 | AVERT
  • Using hepatitis C-infected donor kidneys could reduce time on dialysis for transplant patients with HCV

    Transplanting hepatitis C-infected dialysis patients with HCV-positive donor organs and then treating the infection later is more effective, cheaper and shortens organ wait time.

    10 July 2018 | Eurekalert Inf Dis
  • State Prisons Fail To Offer Cure To 144000 Inmates With Deadly Hepatitis C

    State prisons across the U.S. are failing to treat at least 144,000 inmates who have hepatitis C, a curable but potentially fatal liver disease, according to a recent survey and subsequent interviews of state corrections departments.

    09 July 2018 | Kaiser Health News
  • MSF challenges Gilead's undeserved patent in China on lifesaving hepatitis C medicine

    The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a legal patent challenge today at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent it granted to US pharmaceutical corporation Gilead Sciences in 2012 for the oral hepatitis C medicine velpatasvir. This unmerited patent means this lifesaving medicine could remain priced out of reach for several more years, leaving millions of people to unnecessarily go without in China and abroad.

    20 June 2018 | MSF press release
  • Just 12 countries worldwide on track to eliminate hepatitis C infection by 2030

    Since the last global update in 2017, Italy, Spain, Switzerland, the UK and Mongolia have all been added to the list, thanks to the number of patients they treated in 2017, plus the lifting of treatment restrictions to include all patients with hepatitis C regardless of their degree of liver damage. These countries join the others already on track to eliminate by 2030: Australia, Egypt, France, Georgia, Iceland, Japan and the Netherlands. In all cases, these countries are treating at least 7% of their infected population each year, and have opened treatment up to all those infected.

    18 June 2018 | CDA Foundation
  • Private Payers Deny Hepatitis C Drug Coverage to 52% of Members

    Over half of private payer health plan beneficiaries were denied necessary hepatitis C drug coverage and prescriptions.

    14 June 2018 | Health Payer Intelligence
  • 10 patients safely receive hepatitis C-infected lungs in new clinical trial

    Researchers behind a bold experiment to use hepatitis C-infected lungs for transplant say such organs could help address a critical shortage of donors and make “some good come out” of the increasing number of opioid-related deaths.

    14 June 2018 | CTV
  • EATG launches a report on access to HCV-related services in the penitentiary system in Europe

    Drawing on research on the state of access to services related to Hepatitis C in prison settings in Europe and Central Asia, which has highlighted major shortcomings across the countries as well as some promising practices in few countries, the European AIDS Treatment Group calls on national and prison authorities to scale up access to voluntary and confidential testing and counselling for people in detention.

    23 May 2018 | EATG
  • Do direct acting antivirals cure chronic hepatitis C?

    We were dismayed that the Editors of the BMJ presented the widely discredited Cochrane review of Hepatitis C virus therapy as mainstream opinion. It is not... There is no credible explanation for the fall in hepatitis C liver disease morbidity and mortality associated with the introduction of effective anti-virals other than the use of these drugs.

    18 May 2018 | BMJ
  • How states could be saving more hepatitis C patients

    USC’s Neeraj Sood and colleagues propose an approach that leverages competition among drug manufacturers, saving states money and ensuring that more people get treatment

    15 May 2018 | USC News
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.